The battle for the GLP-1 pill market is heating up, with Novo Nordisk and Eli Lilly both vying for dominance as they prepare for Medicare coverage. The Danish drugmaker, Novo Nordisk, has already achieved a significant milestone with its Wegovy pill, amassing over 3 million prescriptions since its U.S. launch five months ago. This success comes despite the competition from Lilly's Foundayo, which has seen prescriptions rise to 'markedly higher' numbers than the initial 20,000 reported. The tension between these longtime rivals is palpable, with both companies promoting their products at industry events and strategizing for the Medicare program.
Novo's CEO, Mike Doustdar, believes that the Medicare program could be a turning point for Wegovy, especially when compared to Lilly's Zepbound. He argues that Wegovy's additional health benefits, such as reduced risk of cardiovascular issues, make it a more attractive option for seniors. Doustdar's confidence in Wegovy's appeal to older individuals is rooted in his personal perspective, as he would likely choose Wegovy over Zepbound for its comprehensive health advantages.
On the other hand, Lilly's CEO, Dave Ricks, emphasizes convenience as the key selling point for Foundayo. The pill's flexibility in terms of timing and ease of use, especially for seniors on multiple medications, positions it as a more accessible option. Ricks' confidence in the program's popularity stems from Lilly's close collaboration with the government and the belief that obesity care should be integrated into regular health care.
However, both companies face challenges in increasing insurance coverage for GLP-1 drugs. While an analysis suggests cost-effectiveness, employers and health insurance companies are hesitant due to the potential for widespread eligibility and patient discontinuation after achieving weight loss goals. Cigna's recent decision to drop coverage for its employees highlights this issue.
Looking ahead, both companies are developing new drugs to treat obesity. Lilly's retatrutide, a triple agonist, has shown impressive weight loss results, with nearly half of participants losing over 30% of their body weight. The drug's potential for treating higher BMI individuals and its lower strength with fewer side effects are particularly intriguing.
Novo, meanwhile, is developing CagriSema, a combination drug that includes the main ingredient of Wegovy and another molecule. While its efficacy has been somewhat underwhelming compared to Lilly's drugs, Doustdar remains committed to its launch, emphasizing its potential edge in effectiveness.
In conclusion, the GLP-1 pill market is a dynamic and competitive space, with both Novo and Lilly strategizing for Medicare coverage and developing new drugs. The success of Wegovy and Foundayo, along with the emergence of promising new treatments, underscores the evolving landscape of obesity care. As these companies navigate the challenges of insurance coverage and market competition, the future of obesity treatment looks increasingly promising, with potential for better health outcomes and a more integrated approach to care.
